The British Society for Rheumatology biologics register.
about
Biologics registers in RA: methodological aspects, current role and future applications.Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid ArthritisDrug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics RegisterInfluence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent.Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with speciaRisk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics RegisterThe influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era.Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register.Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritisMajor involvement of bacterial components in rheumatoid arthritis and its accompanying oxidative stress, systemic inflammation and hypercoagulability.Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives.Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic.Association between NICE guidance on biologic therapies with rates of hip and knee replacement among rheumatoid arthritis patients in England and Wales: An interrupted time-series analysis.Effect of treatment with biological agents for arthritis in Australia: the Australian Rheumatology Association Database.Is 'class effect' relevant when assessing the benefit/risk profile of a biologic agent?A Threshold Hazard Model for Estimating Serious Infection Risk Following Anti-Tumor Necrosis Factor Therapy in Rheumatoid Arthritis PatientsCost–effectiveness of tumor necrosis factor-α antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
P2860
Q30234303-9D3EA1E9-8BBC-407D-B630-35FE8B5F2313Q30680371-CB68E200-2835-4823-889E-9FDB1D362D36Q31123685-B1515E8E-E78E-49BB-9D8E-3B3CC779A031Q33731716-2A1E8F46-DBDD-42E1-BEC1-F92472CE9727Q34081925-1F3858AC-A8F3-4FC2-8199-907B43D4C479Q34110060-B5554791-B9F5-438D-B01A-9F77F7ECFE42Q34891374-8356D82E-E4FF-4625-BEA7-1BA1BB2C42F9Q34947978-9BB3750C-A3AD-49F2-921D-5B86DCCB5796Q35018415-77B9AD77-6870-4587-BAA6-2BE864308C30Q35605468-A117195E-1383-4DF9-8313-1F33C01C6072Q36020193-178342AC-AE7E-46E5-8CCE-54B56130BBDFQ36064093-D1637963-5F1C-45B9-9560-50BC2AFEBADAQ36732112-FE62A008-43D2-472C-9FD1-F1AC9EA47ED7Q37177593-D7806F44-E5D5-49E9-A222-0F637BF67CA9Q37356217-63F10B17-6409-4D62-BD66-8D178F7805FFQ37632332-87DC9B84-FCE8-4A33-A638-995422EFEBF0Q39113622-734631A9-0719-46EA-89ED-C59A234A7C9FQ39649534-894E0E59-18B7-4E23-9027-463599143BF8Q39665341-5BC28B62-DD3F-43C4-B092-6FAFEDD13A6AQ41687188-5411BBF5-AFBE-4B9F-9900-671780BC4422Q47749650-A243DD29-DAB5-4234-A545-81936B75F0B1Q50155002-DEB980B5-86F6-4C6C-B3D4-2A708D932CB4Q52887542-43EFA277-8D8B-4CD4-A0E3-E3E3EC0981E2Q56969649-3290D08E-7516-4362-83BB-86BBEB4F9F8BQ57658712-85080FF2-6C44-4ED6-AC96-6FF4D37C23E4
P2860
The British Society for Rheumatology biologics register.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The British Society for Rheumatology biologics register.
@ast
The British Society for Rheumatology biologics register.
@en
type
label
The British Society for Rheumatology biologics register.
@ast
The British Society for Rheumatology biologics register.
@en
prefLabel
The British Society for Rheumatology biologics register.
@ast
The British Society for Rheumatology biologics register.
@en
P2093
P2860
P356
P1476
The British Society for Rheumatology biologics register.
@en
P2093
P2860
P304
P356
10.1136/ARD.2005.042499
P407
P478
64 Suppl 4
P577
2005-11-01T00:00:00Z